Stock Analysis
Johnson & Johnson (JNJ) Stock Analysis
Johnson & Johnson (JNJ) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Johnson & Johnson (JNJ) currently has an AIQ Score of 52/100, indicating a neutral setup. Quality is the strongest factor at 71/100. Value is the weakest current factor at 39/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
JNJ at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $257.78 |
| AIQ Score | 52/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | Sell |
| Market Cap | $615.87B |
| P/E Ratio (TTM) | 38.75 |
| Forward P/E | — |
| EPS (quarter ended 2026-09-30) | $0.09 |
| Revenue (quarter ended 2026-09-30) | $25.4B |
| Dividend Yield (TTM) | 2.07% |
| Beta | 0.24 |
| Volume | 6.56M |
| 52-week range | $184.66-$281.07 |
| RSI 14 | 49.17 |
| 50-Day SMA | $265.03 |
| 200-Day SMA | $244.88 |
| Analyst Price Target | $282.00 |
| Next Earnings | Jan 20, 2027 |
JNJJohnson & Johnson
Healthcare / Drug Manufacturers - General
Low Priority
In Line With Peers
Latest quote
- Momentum48
- Value39
- Quality71
- Risk resilience48
- Sentiment58
JNJ Stock Analysis Summary
Johnson & Johnson (JNJ) currently has an AIQ Score of 52/100, indicating a neutral setup. Quality is the strongest factor at 71/100. Value is the weakest current factor at 39/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, JNJ has AIQ Score of 52/100 with Quality base of 71/100 and fading Value at 39/100. Wait for component alignment before adding exposure.
Quality (71/100) leads while Value (39/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · -0.61% stock move · JNJ classified in Drug Manufacturers - General.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is JNJ Bullish or Bearish Right Now?
JNJ currently has a neutral overall setup. Quality is the strongest factor at 71/100, while Value is weakest at 39/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Quality is supportive at 71/100.
- - Analyst target implies +9.40% upside from the latest quote.
- - Value is the current constraint at 39/100.
- - Technical consensus has more sell votes than buy votes (23 vs 15).
Current Consensus
JNJ's Technical Analysis Consensus is currently Sell, with 15 buy, 7 neutral, and 23 sell votes. JNJ's 14-day RSI is 49.17, which places the stock in a neutral momentum range. JNJ's beta is 0.24, indicating lower market sensitivity than the broad market.
What Changed in JNJ?
The largest recent change in JNJ is Momentum moving up by 16.0 points over the available 7-day comparison window. Quality remains the strongest visible factor.
What Would Change the JNJ Outlook?
The current neutral outlook could improve if AIQ moves above 70, momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 40, price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ > 70, RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 40, RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
JNJ Decision Framework
Public evidence layers, setup checks, and risk context for Johnson & Johnson.
Johnson & Johnson (JNJ) Stock Analysis
Johnson & Johnson has an AIQ Score of 52/100 in a Neutral regime. Quality is strongest at 71/100. Beta is 0.24, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | JNJ is in a Neutral AIQ regime with score 52/100. |
| Signal Conflict | The primary conflict is that quality leads at 71/100 while value lags at 39/100. |
| Factor Evidence | Momentum 48/100 · Value 39/100 · Quality 71/100 · Risk 48/100 · Sentiment 58/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Quality is the strongest factor at 71/100.
Momentum is 48/100 and RSI (14) is 49.2.
JNJ is in a Neutral regime at 52/100.
Risk factor is 48/100 with beta 0.24 and annual volatility 20.43%.
Current conflict: quality leads at 71/100 while value lags at 39/100.
JNJ Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
JNJ Fundamentals
JNJ valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
JNJ Technical Analysis
JNJ technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
JNJ Stock Catalysts
Track JNJ earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
JNJ Dividend Analysis
JNJ dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
JNJ Financial Data
JNJ revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
JNJ Risk Analysis
JNJ volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
JNJ Stock News
JNJ stock news, market tone, recent headlines, and catalyst context.
JNJ vs Large-Cap Pharma Peers
Current peer cohort: JNJ · LLY · ABBV · MRK · PFE. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| JNJ Current stock | 52/100 | 39/100 | 48/100 | 48/100 | 1.31 | 20.43% | Current |
| LLY Eli Lilly | 62/100 | 26/100 | 95/100 | 50/100 | 1.36 | 34.89% | JNJ vs LLY |
| ABBV AbbVie | 56/100 | 36/100 | 82/100 | 44/100 | 0.77 | 25.89% | JNJ vs ABBV |
| MRK Merck | 47/100 | 27/100 | 71/100 | 44/100 | 1.88 | 29.63% | JNJ vs MRK |
| PFE Pfizer | 64/100 | 67/100 | 79/100 | 54/100 | 0.81 | 21.51% | JNJ vs PFE |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Oct 21, 2026.
Popular JNJ Comparisons
How JNJ scores against the names it is most often compared with.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts4 recent quarterly periods are available for review.
Checked Oct 21, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Sep 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching JNJ
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for JNJ
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
JNJ Stock FAQ
What is JNJ stock price today?
Johnson & Johnson's current stock price is $257.78. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is JNJ bullish or bearish right now?
JNJ's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is JNJ's market cap?
JNJ's market cap is $615.87B based on the latest completed market-close snapshot from Oct 21, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is JNJ's current P/E ratio?
JNJ's current P/E ratio is 38.75 based on the latest completed market-close snapshot from Oct 21, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is JNJ's RSI?
JNJ's 14-day RSI is 49.17 based on the latest completed market-close snapshot from Oct 21, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is JNJ above its 50-day and 200-day moving averages?
JNJ is -2.74% from its 50-day SMA and 5.27% from its 200-day SMA based on the latest completed market-close snapshot from Oct 21, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is JNJ's next earnings date?
JNJ's next earnings date is currently listed as Jan 20, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does JNJ pay a dividend?
JNJ's dividend yield is 2.07% based on the latest completed market-close snapshot from Oct 21, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.